Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Uni-Bio Science Group Ltd. ( (HK:0690) ) has provided an announcement.
Uni-Bio Science Group Ltd. has announced a strategic partnership with Kexing Biopharm Co., Ltd. to commercialize its osteoporosis treatment, Bogutai®, in six countries including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to tap into a market valued at nearly USD1.5 billion, leveraging Bogutai®’s success in China, where it achieved a 248.9% revenue growth in the first half of 2025. The partnership is expected to enhance Uni-Bio’s global expansion strategy, strengthen its position in the osteoporosis treatment market, and generate long-term value for shareholders.
More about Uni-Bio Science Group Ltd.
Uni-Bio Science Group Ltd. operates in the biopharmaceutical industry, focusing on innovative treatments for osteoporosis. Its primary product, Bogutai®, is a next-generation osteoporosis treatment that offers a convenient and comfortable experience for patients, particularly postmenopausal women at high risk of fractures.
Average Trading Volume: 27,982,361
Technical Sentiment Signal: Buy
Current Market Cap: HK$911.4M
See more insights into 0690 stock on TipRanks’ Stock Analysis page.